Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 8/20 | 0.51 |
| ▸ | CTSS | P25774 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL205184 | 1.00 | CTSK (0.51) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL205183 | 1.00 | CTSK (0.51) | CTSKCTSSMEN1GAAKMT2A | |
| Hydrochloric Acid SCHEMBL2191093 | 0.98 | CTSK (0.50) | CTSKCTSSMEN1GAAKMT2A | |
| Hydrochloric Acid SCHEMBL28031453 | 0.98 | CTSK (0.50) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL376450 | 0.95 | FOLH1 (0.53) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL47004 | 0.95 | FOLH1 (0.53) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL918952 | 0.95 | FOLH1 (0.53) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL30395713 | 0.94 | FOLH1 (0.51) | CTSKCTSSMEN1GAAKMT2A | |
| Hydrochloric Acid SCHEMBL28376761 | 0.94 | FOLH1 (0.51) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL6751878 | 0.94 | FOLH1 (0.51) | CTSKCTSSMEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118146569-B | Hyaluronic acid-artesunate-polyarginine nanoparticle, preparation method and application | 中国海洋大学 | 2024-11-22 | — | — | CN | claimed |
| CN-118986933-A | Nanometer preparation for delivering medicine on demand aiming at inherent barrier of pancreatic cancer, and preparation method and application thereof | 复旦大学 | 2024-11-22 | — | — | CN | claimed |
| CN-118496511-A | Amphiphilic short peptide grafted hyperbranched polymer and preparation method and application thereof | 同济大学 | 2024-08-16 | — | — | CN | claimed |
| CN-118146569-A | Hyaluronic acid-artesunate-polyarginine nanoparticle, preparation method and application | 中国海洋大学 | 2024-06-07 | — | — | CN | claimed |
| CN-115141119-A | Ornithine derivative, preparation method thereof, gadobenate dimeglumine-ornithine complex, preparation and application | 首都医科大学 | 2022-10-04 | — | — | CN | claimed |
| EP-1088020-B1 | FUNCTIONALISED POLYMERS OF ALPHA-AMINO ACIDS AND THE METHOD OF PREPARATION THEREOF | USTAV MAKROMOLEKULARNI CHEMIE (CZ) | 2002-12-18 | — | — | EP | claimed |
| EP-4719381-A1 | LIGAND-POLAR DRUG CONJUGATES | Tripartite Therapeutics Inc. (TW) | 2026-04-08 | — | — | EP | disclosed |
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250368628-A1 | METHODS AND COMPOUNDS FOR MODULATING INHERITED GENETIC DISEASES | DESIGN THERAPEUTICS INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| US-12385042-B2 | Cell-penetrating peptides | VECTIOPEP OÜ (EE) | 2025-08-12 | — | — | US | disclosed |
| CN-120078737-A | Polymer lipid hybrid nanoparticle with T cell activating capability and application thereof | 厦门大学 | 2025-06-03 | — | — | CN | disclosed |
| EP-4558513-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | Merck Sharp & Dohme LLC (US) | 2025-05-28 | — | — | EP | disclosed |
| WO-1999002549-A1 | POLYOL-AMINO ACID COMPOUNDS HAVING ANTI-HELICOBACTER PYLORI ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-01-21 | — | — | WO | disclosed |
| WO-1998038179-A1 | REVERSE HYDROXAMATE DERIVATIVES AS METALLOPROTEASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1998-09-03 | — | — | WO | disclosed |
| US-5710324-A | AMINE CONTAINING COMPOUNDS | MERRELL PHARMACEUTICALS INC. (US) | 1998-01-20 | — | — | US | disclosed |
| WO-1996014844-A1 | CYCLIC AMIDINE ANALOGS AS INHIBITORS OF NITRIC OXIDE SYNTHASE | MERCK & CO., INC. (US) | 1996-05-23 | — | — | WO | disclosed |
| WO-1996001840-A1 | CATIONIC LIPIDS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS | GILEAD SCIENCES, INC. (US) | 1996-01-25 | — | — | WO | disclosed |
| US-5318992-A | Administering for the treatment of hypotensive conditions and shock | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-06-07 | — | — | US | disclosed |
| EP-0446699-A1 | Inhibitors of nitric oxide biosynthesis | MERRELL PHARMACEUTICALS INC. (US) | 1991-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368628-A1 | METHODS AND COMPOUNDS FOR MODULATING INHERITED GENETIC DISEASES | CLN6, GATAD2B, MITF | CTSK 3830/4885CTSS 4237/4885MEN1 3157/4885 |
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | KRAS, NRAS, HRAS | CTSK 1467/4885CTSS 1044/4885MEN1 209/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | CTSK 188/4885CTSS 273/4885MEN1 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.